Not an Ineligible Issuer. The Company currently is not an “ineligible issuer,” as defined in Rule 405 under the Securities Act. The Company agrees to notify XX Xxxxx promptly upon the Company becoming an “ineligible issuer.”
Appears in 6 contracts
Samples: Sales Agreement (Rapid Micro Biosystems, Inc.), Sales Agreement (scPharmaceuticals Inc.), Sales Agreement (Acrivon Therapeutics, Inc.)
Not an Ineligible Issuer. The Company currently is not an “ineligible issuer,” as defined in Rule 405 under of the Securities Actrules and regulation of the Commission. The Company agrees to notify XX Xxxxx promptly upon the Company becoming an “ineligible issuer.”
Appears in 3 contracts
Samples: Sales Agreement (Global Blood Therapeutics, Inc.), Common Stock (Seres Therapeutics, Inc.), Sales Agreement (Seres Therapeutics, Inc.)
Not an Ineligible Issuer. The Company currently is not an “ineligible issuer,” as defined in Rule 405 under the Securities Act. The Company agrees to notify XX Xxxxx promptly upon the Company becoming an “ineligible issuer.”
Appears in 2 contracts
Samples: Sales Agreement (Singular Genomics Systems, Inc.), Sales Agreement (Atreca, Inc.)
Not an Ineligible Issuer. The Company currently is not an “ineligible issuer,” as defined in Rule 405 under the Securities Act. The Company agrees to notify XX Xxxxx the Agent promptly upon the Company becoming an “ineligible issuer.”
Appears in 2 contracts
Samples: Sales Agreement (Olema Pharmaceuticals, Inc.), Sales Agreement (Olema Pharmaceuticals, Inc.)
Not an Ineligible Issuer. The Company currently is not an “ineligible issuer,” as defined in Rule 405 under the Securities Act. The Company agrees to notify XX Xxxxx Wedbush promptly upon the Company becoming an “ineligible issuer.”
Appears in 1 contract
